Nav: Home

Cleveland Clinic Cancer Center experts present data at 2018 ASCO Annual Meeting

June 01, 2018

Friday, June 1, 2018, CLEVELAND: At the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, researchers from Cleveland Clinic Cancer Center will present data from several new studies, including a prospective clinical trial examining non-small cell lung cancer cells' response to immunotherapy; research on germline testing for melanoma; and interim results from a study testing a vaccine for glioblastoma.

"Clinical research is critical to the development of treatment options we can offer patients that extend their lives and improve their quality of life," said Brian Bolwell, M.D., FACP, chairman of Cleveland Clinic Taussig Cancer Institute. "Clinical trials, involving immunotherapy and genomics in particular, are a priority for our cancer center and the research we are presenting at ASCO is a testament to that."

* Abstract 12001 title: Prospective clinical evaluation of blood-based tumor mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC): Interim B-F1RST results; Dr. Vamsidhar Velcheti, oral presenter; Tuesday, June 5

Vamsidhar Velcheti, M.D., FACP, FCCP a medical oncologist at Cleveland Clinic, will announce, in an oral presentation, the interim results of the first prospective trial looking at blood-based tumor mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer. Patients on this clinical trial had a blood-based test for circulating tumor DNA mutation burden before participating in the trial, allowing researchers to perform a post-trial comparison on whether the cancer's genomics were a predictor of response to immunotherapy. Early data, gathered from more than 20 sites, has shown progression-free survival.

Dr. Velcheti is also an author on a study that was the first to examine ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer. A portion of the results were published in Lancet Oncology in April, and at ASCO, updates will be presented. Lastly, Dr. Velcheti was also one of the key investigators in a first-in-human phase 1 clinical trial of loxo-292, a drug targeting RET-fusion positive non-small cell lung cancer, which will be presented at ASCO. This treatment is showing promise in patients with lung cancer harboring this rare form of genomic alteration, and offers a therapeutic alterative with targeted therapy.

* Abstract 2041 title: Phase II trial of SurVaxM combined with standard therapy in patients with newly diagnosed glioblastoma; Dr. Manmeet Ahluwalia, poster presenter; Saturday, June 2

Manmeet Ahluwalia, M.D., a Cleveland Clinic medical oncologist specializing in neuro-oncology, will present a poster on the interim results from a multicenter Phase II study of SurVaxM in patients with newly diagnosed glioblastoma. SurVaxM, is a first-of-its-kind, patented peptide mimic immunotherapeutic vaccine that targets survivin, a cell-survival protein present in most cancers, and is designed to control tumor growth and recurrence. Patients received four priming doses of SurVaxM (500 mcg) with Montanide and sargramostim (100 mcg) every two weeks, followed by adjuvant temozolomide and maintenance SurVaxM every 12 weeks until progression.

Analysis of the first 55 patients showed progression-free survival was 96.3 percent measured from diagnosis and 62.8 percent from first immunization. The 12-month overall survival was 90.9 percent from diagnosis and 70.8 percent from first immunization. The regimen was generally well tolerated and immunization-related adverse events were mild with no serious adverse events attributable to SurVaxM. Researchers concluded standard therapy plus SurVaxM appears promising in glioblastoma compared to standard therapy alone, and the use of SurVaxM is safe in glioblastoma. A randomized, prospective trial of SurVaxM in glioblastoma is planned.

Dr. Ahluwalia is also part of a multi-institutional team examining the efficacy of using tumor DNA to guide treatment for patients with glioblastoma. He and investigators from several leading institutions are participating in a new collaborative effort called ALLELE, to generate prospective clinical genomics and inform treatment decisions such as clinical trial participation in patients with newly diagnosed glioblastoma. The latest data from their work will be presented as an oral at ASCO.

* Abstract 1588 title: Multiplex germline testing in selected melanomas presenting to oncology clinic; Dr. Pauline Funchain, poster presenter; Saturday, June 2

Also at ASCO 2018, Pauline Funchain, M.D., a Cleveland Clinic medical oncologist specializing in melanoma, will present a poster focused on multiplex germline testing in selected melanoma patients. Dr. Funchain's objective was to establish the usefulness of germline testing in the oncologic melanoma population.

In Dr. Funchain's research, a cohort of patients selected based on family or personal history of multiple cancers were offered germline testing with a multiplex panel comprised of 12 genes related to melanoma and 69 additional cancer-related genes not known to be related to melanoma. Dr. Funchain and team concluded that multiplex germline testing in this group resulted in an 18.5 percent mutation-positive rate. Nearly half were identified in genes not previously associated with melanoma, and all genes identified related to increased risks of other cancers. She concluded that patients with melanoma, particularly with a personal or family history of other cancers, may benefit from germline testing, and more data will be required to further refine testing guidelines for melanoma.
About Cleveland Clinic

Cleveland Clinic is a nonprofit multispecialty academic medical center that integrates clinical and hospital care with research and education. Located in Cleveland, Ohio, it was founded in 1921 by four renowned physicians with a vision of providing outstanding patient care based upon the principles of cooperation, compassion and innovation. Cleveland Clinic has pioneered many medical breakthroughs, including coronary artery bypass surgery and the first face transplant in the United States. U.S. News & World Report consistently names Cleveland Clinic as one of the nation's best hospitals in its annual "America's Best Hospitals" survey. Among Cleveland Clinic's 52,000 employees are more than 3,600 full-time salaried physicians and researchers and 14,000 nurses, representing 140 medical specialties and subspecialties. Cleveland Clinic's health system includes a 165-acre main campus near downtown Cleveland, 11 regional hospitals, more than 150 northern Ohio outpatient locations - including 18 full-service family health centers and three health and wellness centers - and locations in Weston, Fla.; Las Vegas, Nev.; Toronto, Canada; Abu Dhabi, UAE; and London, England. In 2017, there were 7.6 million outpatient visits, 229,000 hospital admissions and 207,000 surgical cases throughout Cleveland Clinic's health system. Patients came for treatment from every state and 185 countries. Visit us at Follow us at News and resources available at

Editor's Note: Cleveland Clinic News Service is available to provide broadcast-quality interviews and B-roll upon request.

Cleveland Clinic

Related Cancer Articles:

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.
Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.
Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.
Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.
More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.
New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.
American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.
Oncotarget: Cancer pioneer employs physics to approach cancer in last research article
In the cover article of Tuesday's issue of Oncotarget, James Frost, MD, PhD, Kenneth Pienta, MD, and the late Donald Coffey, Ph.D., use a theory of physical and biophysical symmetry to derive a new conceptualization of cancer.
Health indicators for newborns of breast cancer survivors may vary by cancer type
In a study published in the International Journal of Cancer, researchers from the UNC Lineberger Comprehensive Cancer Center analyzed health indicators for children born to young breast cancer survivors in North Carolina.
Few women with history of breast cancer and ovarian cancer take a recommended genetic test
More than 80 percent of women living with a history of breast or ovarian cancer at high-risk of having a gene mutation have never taken the test that can detect it.
More Cancer News and Cancer Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Listen Again: Reinvention
Change is hard, but it's also an opportunity to discover and reimagine what you thought you knew. From our economy, to music, to even ourselves–this hour TED speakers explore the power of reinvention. Guests include OK Go lead singer Damian Kulash Jr., former college gymnastics coach Valorie Kondos Field, Stockton Mayor Michael Tubbs, and entrepreneur Nick Hanauer.
Now Playing: Science for the People

#562 Superbug to Bedside
By now we're all good and scared about antibiotic resistance, one of the many things coming to get us all. But there's good news, sort of. News antibiotics are coming out! How do they get tested? What does that kind of a trial look like and how does it happen? Host Bethany Brookeshire talks with Matt McCarthy, author of "Superbugs: The Race to Stop an Epidemic", about the ins and outs of testing a new antibiotic in the hospital.
Now Playing: Radiolab

Dispatch 6: Strange Times
Covid has disrupted the most basic routines of our days and nights. But in the middle of a conversation about how to fight the virus, we find a place impervious to the stalled plans and frenetic demands of the outside world. It's a very different kind of front line, where urgent work means moving slow, and time is marked out in tiny pre-planned steps. Then, on a walk through the woods, we consider how the tempo of our lives affects our minds and discover how the beats of biology shape our bodies. This episode was produced with help from Molly Webster and Tracie Hunte. Support Radiolab today at